Longitudinal evaluation of ventricular ejection fraction and NT-proBNP across heart failure subgroups

References

• Shafazand M, Schaufelberger M, Lappas G, et al. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the swedish hospital discharge registry. Eur Heart J. 2009;30:671–678.
   PubMed Web of Science ®Google Scholar
• Levy D, Kenchaiah S, Larsson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–1402.
   PubMed Web of Science ®Google Scholar
• Christiansen MN, Kober L, Weeke P, et al. Age-specific trends in incidence, mortality and comorbidities of heart failure in Denmark, 1995 to 2012. Circulation. 2017;135:1214–1223.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Hjalmarson A, Waagstein F, et al. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1979;1:1374–1376.
   PubMed Web of Science ®Google Scholar
• Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022–1036.
   PubMedGoogle Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717.
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429–1435.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB, CHARM Investigators and Committees, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766.
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, EMPHASIS-HF Study Group, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
   PubMed Web of Science ®Google Scholar
• Metra M, Teerlink JR. Heart failure. Lancet. 2017;390:1981–1995.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
   PubMed Web of Science ®Google Scholar
• Basuray A, French B, Ky B, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation. 2014;129:2380–2387.
   PubMed Web of Science ®Google Scholar
• Wilcox JE, Fonarow GC, Yancy CW, et al. Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. Am Heart J. 2012;163:49–56.
   PubMed Web of Science ®Google Scholar
• Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–269.
   PubMed Web of Science ®Google Scholar
• Andersson C, Vasan RS. Epidemiology of heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10:377–388.
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol. 2016;1:510–518.
   PubMed Web of Science ®Google Scholar
• Rich MW, Beckham RN, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190–1195.
   PubMed Web of Science ®Google Scholar
• Cline CM, Boman K, Holst M, et al. The management of heart failure in Sweden. Eur J Heart Fail. 2002;4:373–376.
   PubMed Web of Science ®Google Scholar
• Cline CM, Israelsson BY, Willenheimer RB, et al. Cost effective management programme for heart failure reduces hospitalisation. Heart. 1998;80:442–446.
   PubMed Web of Science ®Google Scholar
• West JA, Miller NH, Parker KM, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol. 1997;79:58–63.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Patel JJ, Whittaket CT. Tachycardia-induced heart failure. Perm J. 2007;11:50–52.
   PubMedGoogle Scholar
• Nerheim P, Birger-Botkin S, Piracha L, et al. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004;110:247–252.
   PubMed Web of Science ®Google Scholar
• Breathett K, Allen LA, Udelson J, et al. Changes in left ventricular ejection fraction predict survival and hospitalization in heart failure with reduced ejection fraction. Circ Heart Fail. 2016;9:pii:e002962.
   Web of Science ®Google Scholar
• Dunlay SM, Roger VL, Weston SA, et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5:720–726.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Wood DA, Coats AJS, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20:421–428.
   PubMed Web of Science ®Google Scholar
• Lenzen MJ, Scholte op RWJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart failure survey. Eur Heart J. 2004;25:1214–1220.
   PubMed Web of Science ®Google Scholar
• Jug B, Sebestjen M, Sabovic M, et al. Atrial fibrillation is an independent determinant of increased NT-proBNP levels in outpatients with signs and symptoms of heart failure . Wien Klin Wochenschr. 2009;121:700–706.
   PubMed Web of Science ®Google Scholar
• Corell P, Gustafsson F, Kistorp C, et al. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. Int J Cardiol. 2007;117:395–402.
   PubMed Web of Science ®Google Scholar
• Brambatti M, Guerra F, Matassini MV, et al. Cardiac resynchronization therapy improves ejection fraction and cardiac remodelling regardless of patients’ age. Europace. 2013;15:704–710.
   PubMed Web of Science ®Google Scholar
• McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. 2007;297:2502–2514.
   PubMed Web of Science ®Google Scholar
• Gjesing A, Schou M, Torp-Pedersen C, et al. Patient adherence to evidence-based pharmacotherapy in systolic heart failure and the transition of follow-up from specialized heart failure outpatient clinics to primary care. Eur J Heart Fail. 2013;15:671–678.
   PubMed Web of Science ®Google Scholar
• Dahlstrom U, Hakansson J, Swedberg K, et al. Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. Eur J Heart Fail. 2009;11:92–98.
   PubMed Web of Science ®Google Scholar